Publication of the joint multinational call of the PerMed EP Partnership: 'Personalised Medicine for CARdiovascular, MEtabolic, and kidNey diseases (CARMEN 2026)'

On 25 November 2025, the Ministry of Health (hereinafter referred to as the "MZD") publishes the following information in accordance with Act No. 130/2002 Coll., on the Support of Research, Experimental Development and Innovation from Public Funds and on Amendments to Certain Related Acts (Act on the Support of Research, Experimental Development and Innovation), as amended (hereinafter referred to as the "Act"),

the joint European Partnership for Personalised Medicine (EP PerMed) transnational call on Personalised Medicine for CARdiovascular, MEtabolic, and kidNey diseases ("CARMEN 2026")

Call 2026

Deadline for announcement of results
October 2026

National budget allocation for the call
250 000 EUR

Maximum amount of support per project
125 000 EUR

Maximum aid intensity per project
Table: Maximum possible aid intensity by type of entity and type of research (according to the current version Methodology: European Partnerships in Health)

Applicants
research organisation, enterprise, patient organisations

Project duration
3years / 36 months

Deadlines for submission of project proposals:
Pre-proposals: 10 Feb 2026, 14:00 CET
Full proposals: 9 Jun 2026, 14:00 CEST

Interested parties can participate in the international information webinar on 16 December 2025 (10:00 - 12:00 CET). Registration is available at this link: REGISTRATION

Documents

Conditions for the participation of the Czech applicant in CARMEN 2026

Methodology: European Partnerships for Health

Sub-programme 3: European Partnerships in Health - effective from 22.5.2024

Mandatory attachments of the Czech applicant for Phase 1 (pre-proposals)

  1. Affidavit on behalf of the tenderer or co-tenderer (PO)
  2. Affidavit on behalf of the tenderer or co-tenderer (FO)
  3. Affidavit for research organisations (if applicable)
  4. Affidavit of consortium composition (only if a Czech company is represented in the project)
  5. Budget tableAZV ČR Application Form)

Mandatory annexes of the Czech applicant for Phase 2 (full proposals)

  1. Affidavit of competence;
  2. Updated budget table AZV ČR Application Form)

Other documents

Commission Regulation

Frascati manual

Definition of types of results

The official call documents are available here

Information about the call

The next joint transnational call of the PerMed EP partnership, "Personalised Medicine for CARdiovascular, MEtabolic, and kidNey diseases (CARMEN 2026)",aims to:

  • Development and validation of new personalised therapeutic approaches for cardiovascular, metabolic or renal diseases through testing in relevant pre-clinical models (e.g. human cell cultures, organoids, microbiological models mimicking organ function - "organs-on-chips", disease-specific animal models or in silico models).
  • Identification and validation of molecular markers or advanced technologies to monitor the therapeutic response in patients with these diseases and thus better tailor treatment to individual patients. This may also include evaluation treatment efficacy, adverse effects (including those caused by multiple concomitant drugs) and optimisation of dosing.
  • Identification and validation of markers or diagnostic technologies that can help detect early the risk of disease or prevent its worsening or the development of associated diseases in patients with cardiovascular, metabolic or renal diseases. The aim is to delay or slow the development of cardiovascular-metabolic-kidney syndrome.

Remark:

  • Research projects must focus on cardiovascular, metabolic or kidney disease as the primary cause of disease.
  • Research projects may focus on one specific cardiovascular, metabolic or renal disease, or they may explore their interrelationships.
  • Research focusing only on drug-induced cardiac, metabolic or renal toxicity, i.e. damage to the function of these organs caused by the toxic effect of drugs, is beyond the scope of this challenge.
  • Early phase clinical trials (exploratory, proof-of-concept or sub-studies) can be funded under this call, but large-scale clinical trials are not covered. Proposed projects must be carried out at a scale that allows their completion within the given timetable and budget.

Size of the project consortium

Each project consortium must include at least 3 partners from 3 different EU Member States or associated countries whose funding organisations are participating in the call. Each of these partners must be eligible and apply for funding from the relevant funding organisation. All 3 legal entities must be independent of each other. A maximum of 2 partners per consortium applying for funding from the same funding organisation are allowed. The project coordinator cannot be changed between the first and second phase. In project consortia that include at least 3 eligible funding partners, a maximum of 1 self-funding partner is allowed . The maximum number of partners in a project consortium is 6, which may be increased to 7. A patient organisation may be added as an additional partner.

List of participating countries:

Austria (FWF), Belgium (FWO, F.R.S. - FNRS), Czech Republic (MZČR/AZVČR), Denmark (IFD), Estonia (ETAG), Finland (AKA), France (ANR), Germany (BMFTR/DLR, BMG/DLR, SMWK), Greece (GRSI),Hungary (NKFIH), Iceland (RANNIS), Ireland (TE-RI), ISRAEL (CSO-MOH, ISERD), Italy (IT-MOH, FRRB, RT), Latvia (LZP), Lithuania (LMT), Luxembourg (FNR), Poland (NCBR), Portugal (FCT, VP-GRA, CCDRC), Romania (UEFISCDI), Slovakia (CVTI SR), South Africa (SAMRC), Spain (ISCIII, CSCJA, DA-CAT, CFN), Sweden (SRC), Netherlands (ZonMw), Turkey (TUBITAK).

*The list of participating countries is current as of 25 November 2025.

Call rules:

The call is governed by transnational rules common to applicants from all participating countries. In addition to the transnational rules, Czech applicants must also comply with the national conditions set by the relevant national provider. Applicants participating in applied research projects will therefore have to comply with national conditions based on Sub-programme 3: European Partnerships in Health.

Contact person:

Mgr. Monika Kocmanová
Email: 
Tel: +420 778 973 186

You can also submit questions about the transnational call via email: .